By Rahul Koul
“ We are looking at scaling both technology and geographic reach over the next 3-5 years”
In an exclusive interview, Sarvesh Mutha, Managing Director, IntegriMedical shares his insights on the company’ s major achievements, latest offerings and way forward
By Rahul Koul
What inspired the founding of IntegriMedical, and the key milestones achieved so far?
IntegriMedical was founded in 2020 by Sarvesh Mutha, Ankur Naik, Scott McFarland, and Mark Timm with a clear vision: to transform the way medications are delivered, particularly for individuals with needle phobia. With extensive experience in the healthcare and medical device sectors, the founding team recognized a critical yet often overlooked challenge: needle fear. This affects 20 – 50 % of children and nearly 30 % of adults, leading to missed vaccinations and delayed treatments. Additionally, healthcare professionals face constant risks of needle-stick injuries and crosscontamination. To address these concerns, IntegriMedical developed the Needle-Free Injection System( N- FIS), a non-invasive, needle-free alternative to traditional syringes, designed to enhance safety, comfort, and compliance.
Since its inception, the company has reached several key milestones. In terms of regulatory approvals, N-FIS has successfully undergone clinical validation for safety, efficacy, and ease of use. It has received approvals from the Central Drugs Standard Control Organisation( CDSCO) in India and the CE mark( Europe).
The company has also moved into heathtech
BIOVOICENEWS. COM 43